The catalytic fragment of human 2',3'-cyclic nucleotide 3'-phosphodiesterase (hCNP-CF) has been crystallized by the hanging-drop vapour-diffusion method using polyethylene glycol 300 as the precipitating agent. The crystals belong to the orthorhombic space group P2(1)2(1)2(1), with unit-cell parameters a = 44.39, b = 55.35, c = 78.76 A. There is one molecule per asymmetric unit. The crystals diffract to at least 1.8 A resolution using synchrotron radiation and are suitable for X-ray structure analysis at high resolution.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1107/S0907444904024126 | DOI Listing |
Commun Biol
January 2025
Stem Cell Project, Tokyo Metropolitan Institute of Medical Science, 2-1-6 Kamikitazawa, Setagaya-ku, Tokyo, 156-8506, Japan.
RNA helicase DEAD-box helicase 1 (DDX1) forms a complex with the RNA ligase 2´,3´-cyclic phosphate and 5´-OH ligase (RTCB), which plays a vital role in non-spliceosomal splicing of tRNA and X-box binding protein 1 (XBP1) mRNA. However, the importance of DDX1 in non-spliceosomal splicing has not been clarified. To analyze the functions of DDX1 in mammalian cells, we generated DDX1 cKO cells from the polyploid human U2OS cell line and found that splicing of intron-containing tRNAs was significantly disturbed in DDX1-deficient cells, whereas endoplasmic reticulum (ER) stress-induced splicing of XBP1 mRNA was unaffected.
View Article and Find Full Text PDFInt J Surg
October 2024
Department of Chemistry, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, Saudi Arabia.
Neurodegeneration refers to the gradual loss of neurons and extensive changes in glial cells like tau inclusions in astrocytes and oligodendrocytes, α-synuclein inclusions in oligodendrocytes and SOD1 aggregates in astrocytes along with deterioration in the motor, cognition, learning, and behavior. Common neurodegenerative disorders are Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), spinocerebellar ataxia (SCA), and supranuclear palsy. There is a lack of effective treatment for neurodegenerative diseases, and scientists are putting their efforts into developing therapies against them.
View Article and Find Full Text PDFFront Immunol
December 2024
Department of Thoracic Surgery, Affiliated Hospital of Nantong University, Nantong, China.
Background: Despite its involvement in nucleotide metabolism, tumor immune landscape, and immunotherapy response, the role of 2'-3'-cyclic guanosine monophosphate-adenosine monophosphate (2',3'-cGAMP) in lung adenocarcinoma (LUAD) remails unelucidated. This study aimed to investigate the antitumor effects of 2',3'-cGAMP in LUAD.
Method: Herein, patients with LUAD were screened for prognostic biomarkers, which were then assessed for sensitivity to immunotherapy and chemotherapy utilizing the "TIDE" algorithm and CellMiner database.
Angiogenin (Ang), an endoribonuclease belonging to the RNase A superfamily, cleaves the anticodon-loops of tRNAs to produce tRNA half molecules. Although previous studies have demonstrated the involvement of Ang in the pathobiology of neurodegenerative disorders, the characterization of Ang-generated tRNA halves in neuronal cells remains limited. This is partly due to the technical limitations of standard RNA-seq methods, which cannot capture Ang-generated RNAs containing a 2',3'-cyclic phosphate (cP).
View Article and Find Full Text PDFJ Neurochem
January 2025
Department of Biomedicine, University of Bergen, Bergen, Norway.
2',3'-Cyclic nucleotide 3'-phosphodiesterase (CNPase) is an abundant constituent of central nervous system non-compact myelin, and its loss in mice and humans causes neurodegeneration. Additionally, CNPase is frequently used as a marker antigen for myelinating cells. The catalytic activity of CNPase, the 3'-hydrolysis of 2',3'-cyclic nucleotides, is well characterised in vitro, but the in vivo function of CNPase remains unclear.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!